Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company Drug

AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer

Fineline Cube May 15, 2026
R&D

Insilico Medicine Identifies Novel ALS Therapeutic Targets via AI Platform PandaOmics

Fineline Cube Jul 11, 2022

China-based Insilico Medicine announced the identification of multiple novel therapeutic targets for amyotrophic lateral sclerosis...

Company Drug

CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review

Fineline Cube Jul 11, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Ultra-Long-Acting Insulin Receives Clinical Trial Approval

Fineline Cube Jul 11, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that its Category 1 therapeutic biologic product...

Company Deals

Aden Secures USD 29.8M Series B+ Funding to Expand DRG/DIP Solutions

Fineline Cube Jul 11, 2022

Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB...

Policy / Regulatory

NMPA Issues New Vaccine Manufacturing and Distribution Rules

Fineline Cube Jul 11, 2022

China’s National Medical Products Administration (NMPA) has released the “Vaccine Manufacturing and Distribution Management Measures,”...

Company Drug

VivaVision Biotech’s VVN539 Enters Phase II Trial for Open-Angle Glaucoma in US

Fineline Cube Jul 11, 2022

China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study...

Company Deals

Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact

Fineline Cube Jul 11, 2022

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...

Company Deals

Hangzhou DAC Bio Partners with Janssen on ADC Development Deal

Fineline Cube Jul 11, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...

Policy / Regulatory

NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms

Fineline Cube Jul 8, 2022

The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...

Company Drug

Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy

Fineline Cube Jul 8, 2022

China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth...

Company Drug

Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors

Fineline Cube Jul 8, 2022

China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...

Company Deals

Rainmed Medical Makes IPO Debut on Hong Kong Exchange with Valuation Over USD 764M

Fineline Cube Jul 8, 2022

Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its...

Company Deals

MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC

Fineline Cube Jul 8, 2022

The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...

Company Drug

Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China

Fineline Cube Jul 8, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...

Company Drug

Dizal Pharma’s DZD1516 Receives NMPA Green Light for HER2+ Breast Cancer Trial

Fineline Cube Jul 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), spun out from AstraZeneca’s China drug discovery unit...

Company Deals

WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing

Fineline Cube Jul 8, 2022

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...

Company Drug

GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial

Fineline Cube Jul 8, 2022

Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...

Company Deals Digital

ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor

Fineline Cube Jul 7, 2022

Hangzhou-based ClouDr Group Ltd (HKG: 9955), a one-stop chronic disease management and smart medical platform,...

Company Deals

Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment

Fineline Cube Jul 7, 2022

China-based Nanjing Baifu Laser Technology Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Medical Device

Oriomics Launches XiaoWeiAn Multi-Tumor Early Screening Product

Fineline Cube Jul 7, 2022

Hangzhou Ao’rui Biological Technology Co., Ltd (Oriomics) announced the market launch of XiaoWeiAn, a multi-tumor...

Posts pagination

1 … 652 653 654 … 666

Recent updates

  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
  • Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes
  • Biogen Reports Positive Phase II CELIA Results for Diranersen, First-in-Class Tau-Targeting ASO Therapy in Early Alzheimer’s Disease
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for RSS0393 Latex in Atopic Dermatitis Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Company Drug

AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer

Company Drug

Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes

Company Drug

Biogen Reports Positive Phase II CELIA Results for Diranersen, First-in-Class Tau-Targeting ASO Therapy in Early Alzheimer’s Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.